Related Experiment Video

Updated: Sep 26, 2025

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge
09:53

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge

Published on: June 15, 2018

7.6K

Myocarsdial-derived miR-29a-regulated DNMTs: A novel therapeutic target for myocardial fibrosis

Di Wu1, Jing Zhang2, Zujin Xiang1

  • 1Department of Cardiology, The First College of Clinical Medical Science, China Three Gorges University & Yichang Central People's Hospital, Yichang 443003, China; Institute of Cardiovascular Diseases, China Three Gorges University, Yichang 443000, China; HuBei Clinical Research Center for Ischemic Cardiovascular Disease, China.

International Journal of Cardiology
|April 22, 2022
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Delivery of Modified mRNA in a Myocardial Infarction Mouse Model06:03

Delivery of Modified mRNA in a Myocardial Infarction Mouse Model

Published on: June 11, 2020

9.3K
Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes09:16

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes

Published on: June 3, 2018

7.4K

Related Concept Videos

Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
25